Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics
- PMID: 25403448
- DOI: 10.1007/s12022-014-9347-2
Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics
Abstract
The aim of the study was to establish if the null cell adenoma (NCA) forms a distinct subgroup with unique clinicopathological characteristics within the nonfunctioning pituitary adenoma group particularly in relation to the silent gonadotroph adenomas (SGAs). We identified 31 patients with the pathological diagnosis of NCA verified by routine histology and immunohistochemistry with distinct differentiation from SGAs by an established negative testing for SF-1 at the Toronto Western Hospital between December 2004 and August 2010. We reviewed their demographic data, clinical features, magnetic resonance imaging, and the histologic variables: MIB-1, FGFR4, and P27. We compared these to 63 SGAs identified within the same period. All the NCAs were macroadenomas with diameter ranging from 15-57 mm and tumor volumes between 1.95-53.5 mm(3). Preoperative cavernous sinus tumor growth was able to predict the presence of a residual after surgery (p = 0.023). Furthermore, preoperative cavernous sinus extension (p = 0.002) and negative P27 expression (p = 0.035) were able to independently predict the subsequent growth of the postoperative tumor residual. Comparing the NCA to SGA, we found that MIB-1 was higher in NCA (mean ± SD = 3.43 ± 2.76 %) compared to SGAs (mean ± SD = 2.49 ± 1.41 %) (p = 0.044). The preoperative and postoperative tumor volume doubling times (TVDTs) displayed a negative correlation in the SGA (r = -0.855, p = 0.002) while in the NCA, a positive correlation was evident (r = 0.718, p = 0.029). Our study suggests that the NCAs are a distinct group with differing behavioral characteristics from the SGAs. It also appears that the finding of cavernous sinus extension on preoperative imaging and a negative P27 expression on immunohistochemistry in NCAs may be valuable tools in predicting residual tumor growth which may impact on postoperative care.
Similar articles
-
Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution.Neurosurg Focus. 2020 Jun;48(6):E13. doi: 10.3171/2020.3.FOCUS20114. Neurosurg Focus. 2020. PMID: 32480370
-
Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers.Pituitary. 2019 Oct;22(5):514-519. doi: 10.1007/s11102-019-00981-9. Pituitary. 2019. PMID: 31401793
-
Correlation between histological subtypes and MRI findings in clinically nonfunctioning pituitary adenomas.Endocr Pathol. 2012 Sep;23(3):151-6. doi: 10.1007/s12022-012-9208-9. Endocr Pathol. 2012. PMID: 22569896
-
[Pituitary adenomas: neurosurgical treatment].Wien Klin Wochenschr. 2003;115 Suppl 2:28-32. Wien Klin Wochenschr. 2003. PMID: 15518143 Review. German.
-
Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.Turk Patoloji Derg. 2015;31 Suppl 1:4-17. doi: 10.5146/tjpath.2015.01311. Turk Patoloji Derg. 2015. PMID: 26177314 Review.
Cited by
-
Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future.Endocr Pathol. 2023 Mar;34(1):79-97. doi: 10.1007/s12022-023-09755-3. Epub 2023 Feb 17. Endocr Pathol. 2023. PMID: 36797453 Free PMC article. Review.
-
Transcriptomic analysis identifies a tumor subtype mRNA classifier for invasive non-functioning pituitary neuroendocrine tumor diagnostics.Theranostics. 2021 Jan 1;11(1):132-146. doi: 10.7150/thno.47525. eCollection 2021. Theranostics. 2021. PMID: 33391466 Free PMC article.
-
How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020.Cancers (Basel). 2020 Feb 22;12(2):514. doi: 10.3390/cancers12020514. Cancers (Basel). 2020. PMID: 32098443 Free PMC article. Review.
-
Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.Mod Pathol. 2016 Feb;29(2):131-42. doi: 10.1038/modpathol.2015.151. Epub 2016 Jan 8. Mod Pathol. 2016. PMID: 26743473
-
Clinical and Pathological Aspects of Silent Pituitary Adenomas.J Clin Endocrinol Metab. 2019 Jul 1;104(7):2473-2489. doi: 10.1210/jc.2018-00688. J Clin Endocrinol Metab. 2019. PMID: 30020466 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous